Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study
March 01, 2002ByBertrand Coiffier, MD, PhD|C. Fermé|Olivier Hermine, MD, PhD|C. Haioun|E. Baumelou|P. Solal-Celigny|A. Delmer|C. Sebban|N. Mounier|G. Tertian|A. Van Hoof|A. Bosly
At the 2000 Annual Meeting of the American Society of Hematology, we presented the benefits of rituximab (Rituxan) combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone), known as R-CHOP, in comparison with CHOP alone for the treatment of elderly patients with diffuse large B-cell lymphoma (DLCL).